Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge

Journal of Immunology

Volumn 187, Issue 12, 2011, Pages 6417-6427

  Kushawaha, Pramod K ^a   Gupta, Reema ^a   Sundar, Shyam ^b   Sahasrabuddhe, Amogh A ^a   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ELONGATION FACTOR 2; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; PARASITE ANTIGEN; RECOMBINANT ELONGATION FACTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; LEISHMANIA DONOVANI; LYMPHOCYTE PROLIFERATION; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SCHOOL CHILD; SYRIAN HAMSTER; TH1 CELL; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; ANIMALS; CELL LINE; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; CLONAL SELECTION, ANTIGEN-MEDIATED; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; LEISHMANIA DONOVANI; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MALE; MESOCRICETUS; MICE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROTOZOAN PROTEINS; TH1 CELLS;

EID: 83755195794     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102081     Document Type: Article

References (49)

1. Herwaldt, B. L. 1999. Leishmaniasis. Lancet 354: 1191-1199. (Pubitemid 29460458)
2. Guerin, P. J., P. Olliaro, S. Sundar, M. Boelaert, S. L. Croft, P. Desjeux, M. K. Wasunna, and A. D. Bryceson. 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. 2: 494-501. (Pubitemid 34826855)
3. Singh, S. P., D. C. Reddy, M. Rai, and S. Sundar. 2006. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop. Med. Int. Health 11: 899-905. (Pubitemid 43846450)
4. Singh, V. P., A. Ranjan, R. K. Topno, R. B. Verma, N. A. Siddique, V. N. Ravidas, N. Kumar, K. Pandey, and P. Das. 2010. Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India. Am. J. Trop. Med. Hyg. 82: 9-11.
5. Desjeux, P. 2004. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27: 305-318. (Pubitemid 38842803)
6. Handman, E. 2001. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14: 229-243. (Pubitemid 32294669)
7. Haldar, J. P., S. Ghose, K. C. Saha, and A. C. Ghose. 1983. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect. Immun. 42: 702-707. (Pubitemid 14230268)
8. Karp, C. L., S. H. el-Safi, T. A. Wynn, M. M. Satti, A. M. Kordofani, F. A. Hashim, M. Hag-Ali, F. A. Neva, T. B. Nutman, and D. L. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Invest. 91: 1644-1648. (Pubitemid 23127368)
9. Peruhype-Magalhães, V., O. A. Martins-Filho, A. Prata, Lde. A. Silva, A. Rabello, A. Teixeira-Carvalho, R. M. Figueiredo, S. F. Guimarães-Carvalho, T. C. Ferrari, and R. Correa-Oliveira. 2005. Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand. J. Immunol. 62: 487-495.
10. Kemp, M., J. A. Kurtzhals, K. Bendtzen, L. K. Poulsen, M. B. Hansen, D. K. Koech, A. Kharazmi, and T. G. Theander. 1993. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect. Immun. 61: 1069-1073. (Pubitemid 23059669)
11. Murray, H. W., J. Hariprashad, and R. L. Coffman. 1997. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J. Exp. Med. 185: 867-874. (Pubitemid 27119870)
12. Bhowmick, S., R. Ravindran, and N. Ali. 2007. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 25: 6544-6556. (Pubitemid 47198915)
13. Reed, S. G., and P. Scott. 1993. T-cell and cytokine responses in leishmaniasis. Curr. Opin. Immunol. 5: 524-531. (Pubitemid 23250290)
14. Skeiky, Y. A., M. Kennedy, D. Kaufman, M. M. Borges, J. A. Guderian, J. K. Scholler, P. J. Ovendale, K. S. Picha, P. J. Morrissey, K. H. Grabstein, et al. 1998. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 161: 6171-6179. (Pubitemid 28535990)
15. Coler, R. N., Y. A. Skeiky, K. Bernards, K. Greeson, D. Carter, C. D. Cornellison, F. Modabber, A. Campos-Neto, and S. G. Reed. 2002. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70: 4215-4225. (Pubitemid 34790930)
16. Garg, R., S. K. Gupta, P. Tripathi, S. Naik, S. Sundar, and A. Dube. 2005. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin. Exp. Immunol. 140: 149-156. (Pubitemid 40461084)
17. Pirmez, C., M. Yamamura, K. Uyemura, M. Paes-Oliveira, F. Conceição-Silva, and R. L. Modlin. 1993. Cytokine patterns in the pathogenesis of human leishmaniasis. J. Clin. Invest. 91: 1390-1395. (Pubitemid 23127337)
18. Russo, D. M., R. J. Armitage, M. Barral-Netto, A. Barral, K. H. Grabstein, and S. G. Reed. 1993. Antigen-reactive gamma delta T cells in human leishmaniasis. J. Immunol. 151: 3712-3718. (Pubitemid 23282683)
19. Gupta, S. K., B. S. Sisodia, S. Sinha, K. Hajela, S. Naik, A. K. Shasany, and A. Dube. 2007. Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics 7: 816-823. (Pubitemid 46450658)
20. Dube, A., N. Singh, S. Sundar, and N. Singh. 2005. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol. Res. 96: 216-223. (Pubitemid 40933669)
21. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
22. Assreuy, J., F. Q. Cunha, M. Epperlein, A. Noronha-Dutra, C. A. O'Donnell, F. Y. Liew, and S. Moncada. 1994. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur. J. Immunol. 24: 672-676. (Pubitemid 24076634)
23. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76: 4350-4354. (Pubitemid 9256559)
24. Ding, A. H., C. F. Nathan, and D. J. Stuehr. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 141: 2407-2412.
25. Melby, P. C., V. V. Tryon, B. Chandrasekar, and G. L. Freeman. 1998. Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect. Immun. 66: 2135-2142. (Pubitemid 28194113)
26. Samant, M., R. Gupta, S. Kumari, P. Misra, P. Khare, P. K. Kushawaha, A. A. Sahasrabuddhe, and A. Dube. 2009. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis. J. Immunol. 183: 470-479.
27. Kumari, S., M. Samant, P. Misra, P. Khare, B. Sisodia, A. K. Shasany, and A. Dube. 2008. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1kDa offers long-lasting protection against experimental visceral leishmaniasis. Vaccine 26: 5700-5711.
28. Vickers, T. J., S. Wyllie, and A. H. Fairlamb. 2004. Leishmania major elongation factor 1B complex has trypanothione S-transferase and peroxidase activity. J. Biol. Chem. 279: 49003-49009. (Pubitemid 39642165)
29. Nandan, D., A. Cherkasov, R. Sabouti, T. Yi, and N. E. Reiner. 2003. Molecular cloning, biochemical and structural analysis of elongation factor-1 alpha from Leishmania donovani: comparison with the mammalian homologue. Biochem. Biophys. Res. Commun. 302: 646-652. (Pubitemid 36294021)
30. Lopez, M., A. Cherkasov, and D. Nandan. 2007. Molecular architecture of leishmania EF-1alpha reveals a novel site that may modulate protein translation: a possible target for drug development. Biochem. Biophys. Res. Commun. 356: 886-892.
31. Kumari, S., M. Samant, P. Khare, S. Sundar, S. Sinha, and A. Dube. 2008. Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa. Vaccine 26: 4813-4818.
32. Liew, F. Y., Y. Li, D. Moss, C. Parkinson, M. V. Rogers, and S. Moncada. 1991. Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophages. Eur. J. Immunol. 21: 3009-3014.
33. Belosevic, M., D. S. Finbloom, P. H. Van Der Meide, M. V. Slayter, and C. A. Nacy. 1989. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J. Immunol. 143: 266-274. (Pubitemid 19174230)
34. Holaday, B. J., M. D. Sadick, Z. E. Wang, S. L. Reiner, F. P. Heinzel, T. G. Parslow, and R. M. Locksley. 1991. Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines. J. Immunol. 147: 1653-1658.
35. MacMicking, J., Q. W. Xie, and C. Nathan. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15: 323-350. (Pubitemid 27169284)
36. Burns, J. M., Jr., J. M. Scott, E. M. Carvalho, D. M. Russo, C. J. March, K. P. Van Ness, and S. G. Reed. 1991. Characterization of a membrane antigen of Leishmania amazonensis that stimulates human immune responses. J. Immunol. 146: 742-748.
37. Russo, D. M., J. M. Burns, Jr., E. M. Carvalho, R. J. Armitage, K. H. Grabstein, L. L. Button, W. R. McMaster, and S. G. Reed. 1991. Human T cell responses to gp63, a surface antigen of Leishmania. J. Immunol. 147: 3575-3580.
38. White, A. C., Jr., M. Castes, L. Garcia, D. Trujillo, and L. Zambrano. 1992. Leishmania chagasi antigens recognized in cured visceral leishmaniasis and asymptomatic infection. Am. J. Trop. Med. Hyg. 46: 123-131.
39. Bosque, F., N. G. Saravia, L. Valderrama, and G. Milon. 2000. Distinct innate and acquired immune responses to Leishmania in putative susceptible and resistant human populations endemically exposed to L. (Viannia) panamensis infection. Scand. J. Immunol. 51: 533-541. (Pubitemid 30253216)
40. Costa, S. R., A. D'Oliveira, Jr., O. Bacellar, and E. M. Carvalho. 1999. T cell response of asymptomatic Leishmania chagasi infected subjects to recombinant leishmania antigens. Mem. Inst. Oswaldo Cruz 94: 367-370. (Pubitemid 129581191)
41. Bogdan, C., H. Moll, W. Solbach, and M. Röllinghoff. 1990. Tumor necrosis factor-alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur. J. Immunol. 20: 1131-1135. (Pubitemid 20206069)
42. Liew, F. Y., S. Millott, Y. Li, R. Lelchuk, W. L. Chan, and H. Ziltener. 1989. Macrophage activation by interferon-gamma from host-protective T cells is inhibited by interleukin (IL)3 and IL4 produced by disease-promoting T cells in leishmaniasis. Eur. J. Immunol. 19: 1227-1232. (Pubitemid 19196900)
43. Titus, R. G., B. Sherry, and A. Cerami. 1989. Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J. Exp. Med. 170: 2097-2104. (Pubitemid 20010087)
44. Wanidworanun, C., and W. Strober. 1993. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J. Immunol. 151: 6853-6861. (Pubitemid 24001060)
45. Chomarat, P., M. C. Rissoan, J. Banchereau, and P. Miossec. 1993. Interferon gamma inhibits interleukin 10 production by monocytes. J. Exp. Med. 177: 523-527. (Pubitemid 23117103)
46. Trinchieri, G. 1993. Interleukin-12 and its role in the generation of TH1 cells. Immunol. Today 14: 335-338. (Pubitemid 23198164)
47. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170: 827-845. (Pubitemid 19226667)
48. Manetti, R., P. Parronchi, M. G. Giudizi, M. P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177: 1199-1204. (Pubitemid 23097410)
49. Scott, P. 1993. IL-12: initiation cytokine for cell-mediated immunity. Science 260: 496-497. (Pubitemid 23161612)